Lake Street Capital Begins Coverage on OrthoPediatrics (NASDAQ:KIDS)

Stock analysts at Lake Street Capital started coverage on shares of OrthoPediatrics (NASDAQ:KIDS) in a research note issued to investors on Monday, Marketbeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. Lake Street Capital’s target price would indicate a potential upside of 69.96% from the company’s current price.

Several other research analysts have also weighed in on KIDS. Stifel Nicolaus reduced their target price on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Truist Financial cut their price objective on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Finally, Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, March 5th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, OrthoPediatrics presently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $21.77 on Monday. The company has a current ratio of 7.17, a quick ratio of 3.68 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $528.73 million, a P/E ratio of -17.70 and a beta of 1.17. The business has a 50-day moving average of $24.30 and a 200-day moving average of $24.84. OrthoPediatrics has a 1 year low of $21.02 and a 1 year high of $35.99.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $52.67 million during the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same quarter in the previous year, the company earned ($0.23) earnings per share. On average, equities analysts anticipate that OrthoPediatrics will post -0.93 EPS for the current year.

Insider Buying and Selling

In other news, CFO Fred Hite sold 6,443 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total value of $160,172.98. Following the completion of the transaction, the chief financial officer now owns 207,989 shares in the company, valued at $5,170,606.54. This trade represents a 3.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gregory A. Odle sold 5,359 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $133,224.74. Following the completion of the sale, the insider now directly owns 148,788 shares in the company, valued at approximately $3,698,869.68. This represents a 3.48 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in shares of OrthoPediatrics by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 883,221 shares of the company’s stock worth $23,944,000 after purchasing an additional 122,846 shares in the last quarter. Barclays PLC increased its holdings in OrthoPediatrics by 319.3% during the third quarter. Barclays PLC now owns 25,298 shares of the company’s stock worth $686,000 after buying an additional 19,264 shares during the last quarter. Geode Capital Management LLC raised its position in OrthoPediatrics by 2.1% during the third quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock worth $10,615,000 after acquiring an additional 7,972 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in OrthoPediatrics by 125.1% in the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock valued at $94,000 after acquiring an additional 1,929 shares during the last quarter. Finally, Centiva Capital LP bought a new position in shares of OrthoPediatrics in the 3rd quarter valued at about $319,000. 69.05% of the stock is currently owned by institutional investors.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.